TORONTO, May 31, 2022 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces that TauRx Pharmaceuticals Ltd. (“TauRx”), a leader in tau-based research in Alzheimer’s, unveiled initial data from the randomised portion of their widely followed Phase 3 clinical trial, LUCIDITY (NCT03446001). Dundee holds 1,015,008 shares in TauRx. For a copy of TauRx’s official announcement, please visit:
TauRx Announcement Highlights:
- LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (“HMTM”) decline at a rate substantially less than is typical in Alzheimer’s based on published research.
- Safety profile is favourable and consistent with previous HMTM studies.
- TauRx will now pursue regulatory submission and coverage for HMTM.
TauRx reports their lead investigative oral drug, HMTM, was tested in 598 people afflicted with Alzheimer’s. TauRx announced participants of the 12-month blinded phase of the study have moved to an additional one-year open label phase.
According to TauRx’s announcement, Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx, commented: “The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies”.
TauRx advises their data analysis is ongoing and will be reported at a later date. Meanwhile, TauRx will be providing an update on their progress at the 35th Global Conference of Alzheimer’s Disease on June 9th, 2022.
ABOUT DUNDEE CORPORATION:
Dundee Corporation is a public Canadian independent holding company, listed on the Toronto Stock Exchange under the symbol “DC.A”. Through its operating subsidiaries, Dundee Corporation is an active investor focused on delivering long-term, sustainable value as a trusted partner in the mining sector with more than 30 years of experience making accretive mining investments.
FORWARD-LOOKING STATEMENTS:
This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects Dundee Corporation’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Dundee Corporation’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under “Risk Factors” in the Annual Information Form of Dundee Corporation and subsequent filings made with securities commissions in Canada. Dundee Corporation does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
FOR FURTHER INFORMATION PLEASE CONTACT:
Investor and Media Relations
T: (416) 864-3584
E: ir@dundeecorporation.com
